Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 41 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer MOST POPULAR Some Children with Liver Cancer May Need Less Chemotherapy, Study Suggests May 9, 2019 First-Line Serplulimab in Combination with Chemotherapy Improves Survival in Patients with... February 14, 2023 Aspartame and cancer – sweet nothings? July 14, 2023 Study Identifies Hundreds of Potential Targets for Cancer Drugs September 11, 2024 Load more HOT NEWS Results of Continuous vs Intermittent Dosing Schedules of BRAF/MEK Inhibitor Combination... Study Suggests a Link between Stress and Cancer Coming Back “The power of science”: HPV vaccine proven to dramatically reduce cervical... New Combination of Old Drugs Improves Survival in Patients with Prostate...
